Financhill
Sell
37

STXS Quote, Financials, Valuation and Earnings

Last price:
$1.72
Seasonality move :
1.44%
Day range:
$1.70 - $1.78
52-week range:
$1.66 - $3.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.41x
P/B ratio:
24.18x
Volume:
305.2K
Avg. volume:
623.7K
1-year change:
-33.72%
Market cap:
$147M
Revenue:
$26.9M
EPS (TTM):
-$0.30

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
STXS
Stereotaxis
$6.9M -$0.07 -0.07% -20.83% $4.50
AXGN
Axogen
$48.3M $0.02 17.84% -76% $25.71
ELMD
Electromed
$15.8M -- 13.91% -- $37.00
IRIX
IRIDEX
$12.8M -$0.12 -2.72% -18.18% --
MYO
Myomo
$9.2M -$0.08 145.61% -24% $9.25
TMDX
TransMedics Group
$123.4M $0.24 27.41% -31.06% $102.86
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
STXS
Stereotaxis
$1.71 $4.50 $147M -- $0.00 0% 5.41x
AXGN
Axogen
$17.81 $25.71 $789.8M -- $0.00 0% 4.21x
ELMD
Electromed
$24.19 $37.00 $207M 32.25x $0.00 0% 3.63x
IRIX
IRIDEX
$0.99 -- $16.5M -- $0.00 0% 0.33x
MYO
Myomo
$4.85 $9.25 $166.7M -- $0.00 0% 5.63x
TMDX
TransMedics Group
$68.27 $102.86 $2.3B 67.59x $0.00 0% 5.45x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
STXS
Stereotaxis
-- 1.683 -- 0.74x
AXGN
Axogen
31.37% 1.667 6.53% 1.88x
ELMD
Electromed
-- 1.939 -- 4.68x
IRIX
IRIDEX
51.25% 1.717 9.47% 0.73x
MYO
Myomo
-- 2.090 -- 2.82x
TMDX
TransMedics Group
69.02% 2.597 24.3% 7.25x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
STXS
Stereotaxis
$3.2M -$7.6M -139.2% -139.2% -120.3% $1.3M
AXGN
Axogen
$37.6M $2M -6.89% -10.21% 4.56% $7.9M
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
IRIX
IRIDEX
$4.3M -$1.9M -146.36% -157.91% -16.15% -$3.1M
MYO
Myomo
$8.6M -$245.3K -48.64% -48.64% -2.03% $2.5M
TMDX
TransMedics Group
$72M $8.6M 5.12% 19.17% 8.68% $6.1M

Stereotaxis vs. Competitors

  • Which has Higher Returns STXS or AXGN?

    Axogen has a net margin of -118.53% compared to Stereotaxis's net margin of 0.91%. Stereotaxis's return on equity of -139.2% beat Axogen's return on equity of -10.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    AXGN
    Axogen
    76.06% $0.01 $151.4M
  • What do Analysts Say About STXS or AXGN?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 163.16%. On the other hand Axogen has an analysts' consensus of $25.71 which suggests that it could grow by 44.38%. Given that Stereotaxis has higher upside potential than Axogen, analysts believe Stereotaxis is more attractive than Axogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    AXGN
    Axogen
    5 0 0
  • Is STXS or AXGN More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison Axogen has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.487%.

  • Which is a Better Dividend Stock STXS or AXGN?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or AXGN?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than Axogen quarterly revenues of $49.4M. Stereotaxis's net income of -$7.5M is lower than Axogen's net income of $450K. Notably, Stereotaxis's price-to-earnings ratio is -- while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.41x versus 4.21x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.41x -- $6.3M -$7.5M
    AXGN
    Axogen
    4.21x -- $49.4M $450K
  • Which has Higher Returns STXS or ELMD?

    Electromed has a net margin of -118.53% compared to Stereotaxis's net margin of 12.11%. Stereotaxis's return on equity of -139.2% beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About STXS or ELMD?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 163.16%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 52.96%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    ELMD
    Electromed
    2 0 0
  • Is STXS or ELMD More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

  • Which is a Better Dividend Stock STXS or ELMD?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or ELMD?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than Electromed quarterly revenues of $16.3M. Stereotaxis's net income of -$7.5M is lower than Electromed's net income of $2M. Notably, Stereotaxis's price-to-earnings ratio is -- while Electromed's PE ratio is 32.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.41x versus 3.63x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.41x -- $6.3M -$7.5M
    ELMD
    Electromed
    3.63x 32.25x $16.3M $2M
  • Which has Higher Returns STXS or IRIX?

    IRIDEX has a net margin of -118.53% compared to Stereotaxis's net margin of -16.69%. Stereotaxis's return on equity of -139.2% beat IRIDEX's return on equity of -157.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    IRIX
    IRIDEX
    37.33% -$0.12 $5.4M
  • What do Analysts Say About STXS or IRIX?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 163.16%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 101.86%. Given that Stereotaxis has higher upside potential than IRIDEX, analysts believe Stereotaxis is more attractive than IRIDEX.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    IRIX
    IRIDEX
    0 0 0
  • Is STXS or IRIX More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.

  • Which is a Better Dividend Stock STXS or IRIX?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or IRIX?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than IRIDEX quarterly revenues of $11.6M. Stereotaxis's net income of -$7.5M is lower than IRIDEX's net income of -$1.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.41x versus 0.33x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.41x -- $6.3M -$7.5M
    IRIX
    IRIDEX
    0.33x -- $11.6M -$1.9M
  • Which has Higher Returns STXS or MYO?

    Myomo has a net margin of -118.53% compared to Stereotaxis's net margin of -2.16%. Stereotaxis's return on equity of -139.2% beat Myomo's return on equity of -48.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    MYO
    Myomo
    71.39% -$0.01 $24.7M
  • What do Analysts Say About STXS or MYO?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 163.16%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 90.72%. Given that Stereotaxis has higher upside potential than Myomo, analysts believe Stereotaxis is more attractive than Myomo.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    MYO
    Myomo
    3 0 0
  • Is STXS or MYO More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

  • Which is a Better Dividend Stock STXS or MYO?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or MYO?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than Myomo quarterly revenues of $12.1M. Stereotaxis's net income of -$7.5M is lower than Myomo's net income of -$260.1K. Notably, Stereotaxis's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.41x versus 5.63x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.41x -- $6.3M -$7.5M
    MYO
    Myomo
    5.63x -- $12.1M -$260.1K
  • Which has Higher Returns STXS or TMDX?

    TransMedics Group has a net margin of -118.53% compared to Stereotaxis's net margin of 5.64%. Stereotaxis's return on equity of -139.2% beat TransMedics Group's return on equity of 19.17%.

    Company Gross Margin Earnings Per Share Invested Capital
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
    TMDX
    TransMedics Group
    59.21% $0.19 $737.9M
  • What do Analysts Say About STXS or TMDX?

    Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 163.16%. On the other hand TransMedics Group has an analysts' consensus of $102.86 which suggests that it could grow by 50.66%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    STXS
    Stereotaxis
    2 0 0
    TMDX
    TransMedics Group
    5 3 0
  • Is STXS or TMDX More Risky?

    Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.138, suggesting its more volatile than the S&P 500 by 113.849%.

  • Which is a Better Dividend Stock STXS or TMDX?

    Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios STXS or TMDX?

    Stereotaxis quarterly revenues are $6.3M, which are smaller than TransMedics Group quarterly revenues of $121.6M. Stereotaxis's net income of -$7.5M is lower than TransMedics Group's net income of $6.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 67.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 5.41x versus 5.45x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    STXS
    Stereotaxis
    5.41x -- $6.3M -$7.5M
    TMDX
    TransMedics Group
    5.45x 67.59x $121.6M $6.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is it Too Late to Buy United Airlines Stock?
Is it Too Late to Buy United Airlines Stock?

United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…

3 Smartest Dividend Stocks to Buy Now
3 Smartest Dividend Stocks to Buy Now

When the market entered a correction in February and March,…

How High Could IBIT Go?
How High Could IBIT Go?

Recently, a surprising number of billionaire hedge fund managers have…

Stock Ideas

Buy
56
Is AAPL Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 37x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Sell
42
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Buy
100
DLICY alert for Apr 2

Dai-ichi Life Holdings [DLICY] is up 100.91% over the past day.

Buy
78
GATE alert for Apr 2

Marblegate Acquisition [GATE] is up 86.64% over the past day.

Sell
15
PCVX alert for Apr 2

Vaxcyte [PCVX] is down 14.62% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock